Masimo’s revolutionary SET® pulse oximetry has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies – even before the revisions that achieved ...
Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET ® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical ...
Zacks Investment Research on MSN
Masimo SET shows accurate pulse oximetry in newborns of all skin tones
Masimo MASI recently reported findings from the NeoPODS study, a large prospective real-world evaluation of its SET pulse oximetry technology in critically ill newborns. The study demonstrated less ...
Critical congenital heart diseases, or CCHDs, are a group of life-threatening structural heart defects present at birth.
New Neonatal Study Adds to Body of Clinical Evidence Demonstrating Masimo SET ® Pulse Oximetry’s Unique Ability to Improve Care NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) provides ...
Pulse oximetry is a widely used monitoring method for measuring blood oxygen levels and pulse rate. In newborn babies, pulse oximetry can help clinicians conduct screening tests for lung or heart ...
Although current pulse-oximetry technology cannot detect every cardiac defect, the rate of missed CCHD diagnoses is much higher when screening is based on physical examination alone. Health-care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results